Bacterial Respiratory Infections Complicating Human Immunodeficiency Virus

Seminars in Respiratory and Critical Care Medicine

Volumn 37, Issue 2, 2016, Pages 214-229

  Feldman, Charles ^a   Anderson, Ronald ^b  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b UNIVERSITY OF PRETORIA   (South Africa)

Author keywords

community acquired pneumonia; host defenses; outcome; pneumococcal immunization; pneumococcus; risk factors; severity of illness; treatment

Indexed keywords

PNEUMOCOCCUS VACCINE; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; COMMUNITY ACQUIRED PNEUMONIA; DISEASE SEVERITY; HAEMOPHILUS INFLUENZAE; HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; LABORATORY DIAGNOSIS; LOWER RESPIRATORY TRACT INFECTION; MICROBIOME; MORAXELLA CATARRHALIS; MORTALITY; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RHODOCOCCUS HOAGII; RISK FACTOR; SMOKING; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; ADVERSE EFFECTS; AIDS-RELATED OPPORTUNISTIC INFECTIONS; BACTERIAL INFECTIONS; COMPLICATION; MICROBIOLOGY; PNEUMOCOCCAL INFECTIONS; PROCEDURES; RESPIRATORY TRACT INFECTIONS;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; HIV INFECTIONS; HUMANS; IMMUNIZATION; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; RESPIRATORY TRACT INFECTIONS; RISK FACTORS; SMOKING;

EID: 84960959412     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0036-1572558     Document Type: Article

References (167)

1. Mayaud C., Parrot A., Cadranel J. Pyogenic bacterial lower respiratory tract infection in human immunodeficiency virus-infected patients. Eur Respir J Suppl: 2002; 36 36 28s 39s
2. Benito N., Moreno A., Miro J. M., Torres A. Pulmonary infections in HIV-infected patients: an update in the 21st century. Eur Respir J: 2012; 39 3 730 745
3. Segal L. N., Methé B. A., Nolan A., et al. HIV-1 and bacterial pneumonia in the era of antiretroviral therapy. Proc Am Thorac Soc: 2011; 8 3 282 287
4. Brown J., Lipman M. Community-acquired pneumonia in HIV-infected individuals. Curr Infect Dis Rep: 2014; 16 3 397
5. Feldman C., Anderson R. HIV-associated bacterial pneumonia. Clin Chest Med: 2013; 34 2 205 216
6. Feldman C., Anderson R. Respiratory infections in specific populations: HIV patients. In: Blasi F., Dimopoulos G. eds. Textbook of Respiratory and Critical Care Infections. New Delhi, India Jaypee Brothers Medical Publishers: 2015; 139 158
7. Feikin D. R., Feldman C., Schuchat A., Janoff E. N. Global strategies to prevent bacterial pneumonia in adults with HIV disease. Lancet Infect Dis: 2004; 4 7 445 455
8. Boschini A., Smacchia C., Di Fine M., et al. Community-acquired pneumonia in a cohort of former injection drug users with and without human immunodeficiency virus infection: incidence, etiologies, and clinical aspects. Clin Infect Dis: 1996; 23 1 107 113
9. Kohli R., Lo Y., Homel P., et al. HER Study Group. Bacterial pneumonia, HIV therapy, and disease progression among HIV-infected women in the HIV epidemiologic research (HER) study. Clin Infect Dis: 2006; 43 1 90 98
10. Wolff A. J., O'Donnell A. E. Pulmonary manifestations of HIV infection in the era of highly active antiretroviral therapy. Chest: 2001; 120 6 1888 1893
11. Sullivan J. H., Moore R. D., Keruly J. C., Chaisson R. E. Effect of antiretroviral therapy on the incidence of bacterial pneumonia in patients with advanced HIV infection. Am J Respir Crit Care Med: 2000; 162 1 64 67
12. Hirschtick R. E., Glassroth J., Jordan M. C., et al. Pulmonary Complications of HIV Infection Study Group. Bacterial pneumonia in persons infected with the human immunodeficiency virus. N Engl J Med: 1995; 333 13 845 851
13. Tumbarello M., Tacconelli E., de Gaetano K., et al. Bacterial pneumonia in HIV-infected patients: analysis of risk factors and prognostic indicators. J Acquir Immune Defic Syndr Hum Retrovirol: 1998; 18 1 39 45
14. Madeddu G., Porqueddu E. M., Cambosu F., et al. Bacterial community acquired pneumonia in HIV-infected inpatients in the highly active antiretroviral therapy era. Infection: 2008; 36 3 231 236
15. Madeddu G., Laura Fiori M., Stella Mura M. Bacterial community-acquired pneumonia in HIV-infected patients. Curr Opin Pulm Med: 2010; 16 3 201 207
16. Mussini C., Galli L., Lepri A. C., et al. ICONA Foundation Study Group. Incidence, timing, and determinants of bacterial pneumonia among HIV-infected patients: data from the ICONA Foundation Cohort. J Acquir Immune Defic Syndr: 2013; 63 3 339 345
17. Penner J., Meier A. S., Mwachari C., et al. Risk factors for pneumonia in urban-dwelling HIV-infected women: a case-control study in Nairobi, Kenya. J Acquir Immune Defic Syndr: 2003; 32 2 223 228
18. Navin T. R., Rimland D., Lennox J. L., et al. Risk factors for community-acquired pneumonia among persons infected with human immunodeficiency virus. J Infect Dis: 2000; 181 1 158 164
19. Bjerk S. M., Baker J. V., Emery S., et al. INSIGHT SMART Study Group. Biomarkers and bacterial pneumonia risk in patients with treated HIV infection: a case-control study. PLoS ONE: 2013; 8 2 e56249
20. Twigg H. L. III, Knox K. S. Impact of antiretroviral therapy on lung immunology and inflammation. Clin Chest Med: 2013; 34 2 155 164
21. Huson M. A., Grobusch M. P., van der Poll T. The effect of HIV infection on the host response to bacterial sepsis. Lancet Infect Dis: 2015; 15 1 95 108
22. Rossouw T. M., Anderson R., Feldman C. Impact of HIV infection and smoking on lung immunity and related disorders. Eur Respir J: 2015; 46 6 1781 1795
23. Perreau M., Savoye A. L., De Crignis E., et al. Follicular helper T cells serve as the major CD4 T cell compartment for HIV-1 infection, replication, and production. J Exp Med: 2013; 210 1 143 156
24. Jambo K. C., Banda D. H., Kankwatira A. M., et al. Small alveolar macrophages are infected preferentially by HIV and exhibit impaired phagocytic function. Mucosal Immunol: 2014; 7 5 1116 1126
25. Gordon S. B., Jagoe R. T., Jarman E. R., et al. The alveolar microenvironment of patients infected with human immunodeficiency virus does not modify alveolar macrophage interactions with Streptococcus pneumoniae. Clin Vaccine Immunol: 2013; 20 6 882 891
26. Malley R. Antibody and cell-mediated immunity to Streptococcus pneumoniae: implications for vaccine development. J Mol Med (Berl): 2010; 88 2 135 142
27. Crothers K., Griffith T. A., McGinnis K. A., et al. The impact of cigarette smoking on mortality, quality of life, and comorbid illness among HIV-positive veterans. J Gen Intern Med: 2005; 20 12 1142 1145
28. Feldman J. G., Minkoff H., Schneider M. F., et al. Association of cigarette smoking with HIV prognosis among women in the HAART era: a report from the women's interagency HIV study. Am J Public Health: 2006; 96 6 1060 1065
29. Gordin F. M., Roediger M. P., Girard P-M., et al. Pneumonia in HIV-infected persons: increased risk with cigarette smoking and treatment interruption. Am J Respir Crit Care Med: 2008; 178 6 630 636
30. Petrosillo N., Cicalini S. Smoking and HIV: time for a change? BMC Med: 2013; 11 16
31. Helleberg M., Afzal S., Kronborg G., et al. Mortality attributable to smoking among HIV-1-infected individuals: a nationwide, population-based cohort study. Clin Infect Dis: 2013; 56 5 727 734
32. Feldman C., Anderson R. Cigarette smoking and mechanisms of susceptibility to infections of the respiratory tract and other organ systems. J Infect: 2013; 67 3 169 184
33. Sapkota A. R., Berger S., Vogel T. M. Human pathogens abundant in the bacterial metagenome of cigarettes. Environ Health Perspect: 2010; 118 3 351 356
34. Brook I., Gober A. E. Recovery of potential pathogens and interfering bacteria in the nasopharynx of smokers and nonsmokers. Chest: 2005; 127 6 2072 2075
35. Voss M., Wonnenberg B., Honecker A., et al. Cigarette smoke-promoted acquisition of bacterial pathogens in the upper respiratory tract leads to enhanced inflammation in mice. Respir Res: 2015; 16 1 41
36. Kulkarni R., Antala S., Wang A., et al. Cigarette smoke increases Staphylococcus aureus biofilm formation via oxidative stress. Infect Immun: 2012; 80 11 3804 3811
37. Mutepe N. D., Cockeran R., Steel H. C., et al. Effects of cigarette smoke condensate on pneumococcal biofilm formation and pneumolysin. Eur Respir J: 2013; 41 2 392 395
38. Hutcherson J. A., Scott D. A., Bagaitkar J. Scratching the surface - tobacco-induced bacterial biofilms. Tob Induc Dis: 2015; 13 1 1
39. Kearley J., Silver J. S., Sanden C., et al. Cigarette smoke silences innate lymphoid cell function and facilitates an exacerbated type I interleukin-33-dependent response to infection. Immunity: 2015; 42 3 566 579
40. Bourdonnay E., Zasłona Z., Penke L. R., et al. Transcellular delivery of vesicular SOCS proteins from macrophages to epithelial cells blunts inflammatory signaling. J Exp Med: 2015; 212 5 729 742
41. Grigg J., Walters H., Sohal S. S., et al. Cigarette smoke and platelet-activating factor receptor dependent adhesion of Streptococcus pneumoniae to lower airway cells. Thorax: 2012; 67 10 908 913
42. Schamberger A. C., Mise N., Jia J., et al. Cigarette smoke-induced disruption of bronchial epithelial tight junctions is prevented by transforming growth factor-β Am J Respir Cell Mol Biol: 2014; 50 6 1040 1052
43. Lozupone C., Cota-Gomez A., Palmer B. E., et al. Lung HIV Microbiome Project. Widespread colonization of the lung by Tropheryma whipplei in HIV infection. Am J Respir Crit Care Med: 2013; 187 10 1110 1117
44. Cui L., Lucht L., Tipton L., et al. Topographic diversity of the respiratory tract mycobiome and alteration in HIV and lung disease. Am J Respir Crit Care Med: 2015; 191 8 932 942
45. Morris A., Beck J. M., Schloss P. D., et al. Lung HIV Microbiome Project. Comparison of the respiratory microbiome in healthy nonsmokers and smokers. Am J Respir Crit Care Med: 2013; 187 10 1067 1075
46. Sopena N., Pedro-Botet M. L., Sabrià M., García-Parés D., Reynaga E., García-Nuñez M. Comparative study of community-acquired pneumonia caused by Streptococcus pneumoniae, Legionella pneumophila or Chlamydia pneumoniae. Scand J Infect Dis: 2004; 36 5 330 334
47. Chidiac C. Pneumococcal infections and adult with risk factors. Med Mal Infect: 2012; 42 10 517 524
48. Kyaw M. H., Rose C. E. Jr, Fry A. M., et al. Active Bacterial Core Surveillance Program of the Emerging Infections Program Network. The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults. J Infect Dis: 2005; 192 3 377 386
49. Lynch J. P. III, Zhanel G. G. Streptococcus pneumoniae: epidemiology, risk factors, and strategies for prevention. Semin Respir Crit Care Med: 2009; 30 2 189 209
50. Mufson M. A., Hao J. B., Stanek R. J., Norton N. B. Clinical features of patients with recurrent invasive Streptococcus pneumoniae disease. Am J Med Sci: 2012; 343 4 303 309
51. Dworkin M. S., Ward J. W., Hanson D. L., Jones J. L., Kaplan J. E.; Adult and Adolescent Spectrum of HIV Disease Project. Pneumococcal disease among human immunodeficiency virus-infected persons: incidence, risk factors, and impact of vaccination. Clin Infect Dis: 2001; 32 5 794 800
52. Perelló R., Miró O., Marcos M. A., et al. Predicting bacteremic pneumonia in HIV-1-infected patients consulting the ED. Am J Emerg Med: 2010; 28 4 454 459
53. Munier A. L., de Lastours V., Porcher R., Donay J. L., Pons J. L., Molina J. M. Risk factors for invasive pneumococcal disease in HIV-infected adults in France in the highly active antiretroviral therapy era. Int J STD AIDS: 2014; 25 14 1022 1028
54. Jover F., Cuadrado J. M., Andreu L., et al. A comparative study of bacteremic and non-bacteremic pneumococcal pneumonia. Eur J Intern Med: 2008; 19 1 15 21
55. Yin Z., Rice B. D., Waight P., et al. Invasive pneumococcal disease among HIV-positive individuals, 2000-2009. AIDS: 2012; 26 1 87 94
56. Madeddu G., Fois A. G., Pirina P., Mura M. S. Pneumococcal pneumonia: clinical features, diagnosis and management in HIV-infected and HIV noninfected patients. Curr Opin Pulm Med: 2009; 15 3 236 242
57. Feldman C., Klugman K. P., Yu V. L., et al. International Pneumococcal Study Group. Bacteraemic pneumococcal pneumonia: impact of HIV on clinical presentation and outcome. J Infect: 2007; 55 2 125 135
58. Schleicher G. K., Feldman C. Dual infection with Streptococcus pneumoniae and Mycobacterium tuberculosis in HIV-seropositive patients with community acquired pneumonia. Int J Tuberc Lung Dis: 2003; 7 12 1207 1208
59. Sanz J. C., Cercenado E., Marín M., et al. Multidrug-resistant pneumococci (serotype 8) causing invasive disease in HIV+ patients. Clin Microbiol Infect: 2011; 17 7 1094 1098
60. Isea-Peña M. C., Sanz-Moreno J. C., Esteban J., Fernández-Roblas R., Fernández-Guerrero M. L. Risk factors and clinical significance of invasive infections caused by levofloxacin-resistant Streptococcus pneumoniae. Infection: 2013; 41 5 935 939
61. Allen S. H., Brennan-Benson P., Nelson M., et al. Pneumonia due to antibiotic resistant Streptococcus pneumoniae and Pseudomonas aeruginosa in the HAART era. Postgrad Med J: 2003; 79 938 691 694
62. Jordano Q., Falcó V., Almirante B., et al. Invasive pneumococcal disease in patients infected with HIV: still a threat in the era of highly active antiretroviral therapy. Clin Infect Dis: 2004; 38 11 1623 1628
63. Heffernan R. T., Barrett N. L., Gallagher K. M., et al. Declining incidence of invasive Streptococcus pneumoniae infections among persons with AIDS in an era of highly active antiretroviral therapy, 1995-2000. J Infect Dis: 2005; 191 12 2038 2045
64. Saindou M., Chidiac C., Miailhes P., et al. Pneumococcal pneumonia in HIV-infected patients by antiretroviral therapy periods. HIV Med: 2008; 9 4 203 207
65. Siemieniuk R. AC, Gregson D. B., Gill M. J. The persisting burden of invasive pneumococcal disease in HIV patients: an observational cohort study. BMC Infect Dis: 2011; 11 314
66. Nunes M. C., von Gottberg A., de Gouveia L., et al. Persistent high burden of invasive pneumococcal disease in South African HIV-infected adults in the era of an antiretroviral treatment program. PLoS ONE: 2011; 6 11 e27929
67. Falcó V., Burgos J., Pahissa A. The spectrum of invasive pneumococcal disease in adults in the XXI century. Clin Pulm Med: 2013; 20 5 214 220
68. Schlamm H. T., Yancovitz S. R. Haemophilus influenzae pneumonia in young adults with AIDS, ARC, or risk of AIDS. Am J Med: 1989; 86 1 11 14
69. Moreno S., Martinez R., Barros C., Gonzalez-Lahoz J., Garcia-Delgado E., Bouza E. Latent Haemophilus influenzae pneumonia in patients infected with HIV. AIDS: 1991; 5 8 967 970
70. Casadevall A., Dobroszycki J., Small C., Pirofski L. A. Haemophilus influenzae type b bacteremia in adults with AIDS and at risk for AIDS. Am J Med: 1992; 92 6 587 590
71. Rich J. D., Sax P. E., Kazanjian P. H. Bacteremic H. influenzae type b infections and HIV. Am J Med: 1993; 95 1 118 119
72. Muñoz P., Miranda M. E., Llancaqueo A., Peláez T., Rodríguez-Créixems M., Bouza E. Haemophilus species bacteremia in adults. The importance of the human immunodeficiency virus epidemic. Arch Intern Med: 1997; 157 16 1869 1873
73. Cordero E., Pachón J., Rivero A., et al. Haemophilus influenzae pneumonia in human immunodeficiency virus-infected patients. The Grupo Andaluz para el Estudio de las Enfermedades Infecciosas. Clin Infect Dis: 2000; 30 3 461 465
74. Levine S. J., White D. A., Fels A. O. The incidence and significance of Staphylococcus aureus in respiratory cultures from patients infected with the human immunodeficiency virus. Am Rev Respir Dis: 1990; 141 1 89 93
75. Tumbarello M., Tacconelli E., Lucia M. B., Cauda R., Ortona L. Predictors of Staphylococcus aureus pneumonia associated with human immunodeficiency virus infection. Respir Med: 1996; 90 9 531 537
76. Gil Suay V., Cordero P. J., Martínez E., et al. Parapneumonic effusions secondary to community-acquired bacterial pneumonia in human immunodeficiency virus-infected patients. Eur Respir J: 1995; 8 11 1934 1939
77. Lobo L. J., Reed K. D., Wunderink R. G. Expanded clinical presentation of community-acquired methicillin-resistant Staphylococcus aureus pneumonia. Chest: 2010; 138 1 130 136
78. Daneshvar C., Smith N. C., Waghorn D. J., Luzzi G. A., Wathen C. G. Community-acquired pneumonia due to Panton-Valentine leukocidin-producing Staphylococcus aureus in an HIV-2-infected patient. Int J STD AIDS: 2011; 22 10 610 612
79. Tarp B., Jensen J. S., Ostergaard L., Andersen P. L. Search for agents causing atypical pneumonia in HIV-positive patients by inhibitor-controlled PCR assays. Eur Respir J: 1999; 13 1 175 179
80. Sandkovsky U., Sandkovsky G., Suh J., Smith B., Sharp V., Polsky B. Legionella pneumonia and HIV: case reports and review of the literature. AIDS Patient Care STDS: 2008; 22 6 473 481
81. Pedro-Botet M. L., Sabrià M., Sopena N., et al. Legionnaires disease and HIV infection. Chest: 2003; 124 2 543 547
82. Robbins N. M., Kumar A., Blair B. M. Legionella pneumophila infection presenting as headache, confusion and dysarthria in a human immunodeficiency virus-1 (HIV-1) positive patient: case report. BMC Infect Dis: 2012; 12 225
83. Comandini U. V., Maggi P., Santopadre P., Monno R., Angarano G., Vullo V. Chlamydia pneumoniae respiratory infections among patients infected with the human immunodeficiency virus. Eur J Clin Microbiol Infect Dis: 1997; 16 10 720 726
84. Tositti G., Rassu M., Fabris P., et al. Chlamydia pneumoniae infection in HIV-positive patients: prevalence and relationship with lipid profile. HIV Med: 2005; 6 1 27 32
85. Shankar E. M., Kumarasamy N., Vignesh R., et al. Epidemiological studies on pulmonary pathogens in HIV-positive and -negative subjects with or without community-acquired pneumonia with special emphasis on Mycoplasma pneumoniae. Jpn J Infect Dis: 2007; 60 6 337 341
86. Ali N. J., Kessel D., Miller R. F. Bronchopulmonary infection with Pseudomonas aeruginosa in patients infected with human immunodeficiency virus. Genitourin Med: 1995; 71 2 73 77
87. Meynard J. L., Barbut F., Guiguet M., et al. Pseudomonas aeruginosa infection in human immunodeficiency virus infected patients. J Infect: 1999; 38 3 176 181
88. Afessa B., Green B. Bacterial pneumonia in hospitalized patients with HIV infection: the Pulmonary Complications, ICU Support, and Prognostic Factors of Hospitalized Patients with HIV (PIP) Study. Chest: 2000; 117 4 1017 1022
89. Manfredi R., Nanetti A., Ferri M., Chiodo F. Pseudomonas spp. complications in patients with HIV disease: an eight-year clinical and microbiological survey. Eur J Epidemiol: 2000; 16 2 111 118
90. Sadikot R. T., Blackwell T. S., Christman J. W., Prince A. S. Pathogen-host interactions in Pseudomonas aeruginosa pneumonia. Am J Respir Crit Care Med: 2005; 171 11 1209 1223
91. Williams B. J., Dehnbostel J., Blackwell T. S. Pseudomonas aeruginosa: host defence in lung diseases. Respirology: 2010; 15 7 1037 1056
92. Fujitani S., Sun H. Y., Yu V. L., Weingarten J. A. Pneumonia due to Pseudomonas aeruginosa: part I: epidemiology, clinical diagnosis, and source. Chest: 2011; 139 4 909 919
93. Topino S., Galati V., Grilli E., Petrosillo N. Rhodococcus equi infection in HIV-infected individuals: case reports and review of the literature. AIDS Patient Care STDS: 2010; 24 4 211 222
94. Manfredi R., Nanetti A., Valentini R., Chiodo F. Moraxella catarrhalis pneumonia during HIV disease. J Chemother: 2000; 12 5 406 411
95. Smith M. D., Derrington P., Evans R., et al. Rapid diagnosis of bacteremic pneumococcal infections in adults by using the Binax NOW Streptococcus pneumoniae urinary antigen test: a prospective, controlled clinical evaluation. J Clin Microbiol: 2003; 41 7 2810 2813
96. Jorgensen C. S., Uldum S. A., Sorensen J. F., Skovsted I. C., Otte S., Elverdal P. L. Evaluation of a new lateral flow test for detection of Streptococcus pneumoniae and Legionella pneumophila urinary antigen. J Microbiol Methods: 2015; 116 33 36
97. Sheppard C. L., Harrison T. G., Smith M. D., George R. C. Development of a sensitive, multiplexed immunoassay using xMAP beads for detection of serotype-specific streptococcus pneumoniae antigen in urine samples. J Med Microbiol: 2011; 60 Pt 1 49 55
98. Pride M. W., Huijts S. M., Wu K., et al. Validation of an immunodiagnostic assay for detection of 13 Streptococcus pneumoniae serotype-specific polysaccharides in human urine. Clin Vaccine Immunol: 2012; 19 8 1131 1141
99. Elberse K., van Mens S., Cremers A. J., et al. Detection and serotyping of pneumococci in community acquired pneumonia patients without culture using blood and urine samples. BMC Infect Dis: 2015; 15 56
100. Slotved H. C., Kaltoft M., Skovsted I. C., Kerrn M. B., Espersen F. Simple, rapid latex agglutination test for serotyping of pneumococci (Pneumotest-Latex). J Clin Microbiol: 2004; 42 6 2518 2522
101. Kuch A., Goł©biewska A., Was̈ko I., et al. Usefulness of Pneumotest-latex for direct serotyping of Streptococcus pneumoniae isolates in clinical samples. J Clin Microbiol: 2014; 52 7 2647 2649
102. Carvalho MdaG, Tondella M. L., McCaustland K., et al. Evaluation and improvement of real-time PCR assays targeting lytA, ply, and psaA genes for detection of pneumococcal DNA. J Clin Microbiol: 2007; 45 8 2460 2466
103. Werno A. M., Anderson T. P., Murdoch D. R. Association between pneumococcal load and disease severity in adults with pneumonia. J Med Microbiol: 2012; 61 Pt 8 1129 1135
104. Strålin K., Herrmann B., Abdeldaim G., Olcén P., Holmberg H., Mölling P. Comparison of sputum and nasopharyngeal aspirate samples and of the PCR gene targets lytA and Spn9802 for quantitative PCR for rapid detection of pneumococcal pneumonia. J Clin Microbiol: 2014; 52 1 83 89
105. Bogaerts P., Hamels S., de Mendonca R., et al. Analytical validation of a novel high multiplexing real-time PCR array for the identification of key pathogens causative of bacterial ventilator-associated pneumonia and their associated resistance genes. J Antimicrob Chemother: 2013; 68 2 340 347
106. Jamal W., Al Roomi E., AbdulAziz L. R., Rotimi V. O. Evaluation of Curetis Unyvero, a multiplex PCR-based testing system, for rapid detection of bacteria and antibiotic resistance and impact of the assay on management of severe nosocomial pneumonia. J Clin Microbiol: 2014; 52 7 2487 2492
107. Gadsby N. J., McHugh M. P., Russell C. D., et al. Development of two real-time multiplex PCR assays for the detection and quantification of eight key bacterial pathogens in lower respiratory tract infections. Clin Microbiol Infect: 2015; 21 8 788.e1 788.e13
108. Jain S., Self W. H., Wunderink R. G., et al. CDC EPIC Study Team. Community-acquired pneumonia requiring hospitalization among U.S. adults. N Engl J Med: 2015; 373 5 415 427
109. Chamie G., Luetkemeyer A., Walusimbi-Nanteza M., et al. Significant variation in presentation of pulmonary tuberculosis across a high resolution of CD4 strata. Int J Tuberc Lung Dis: 2010; 14 10 1295 1302
110. Piatek A. S., Van Cleeff M., Alexander H., et al. GeneXpert for TB diagnosis: planned and purposeful implementation. Glob Health Sci Pract: 2013; 1 1 18 23
111. Theron G., Peter J., van Zyl-Smit R., et al. Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in a high HIV prevalence setting. Am J Respir Crit Care Med: 2011; 184 1 132 140
112. Hanrahan C. F., Theron G., Bassett J., et al. Xpert MTB/RIF as a measure of sputum bacillary burden. Variation by HIV status and immunosuppression. Am J Respir Crit Care Med: 2014; 189 11 1426 1434
113. Florin T. A., Ambroggio L. Biomarkers for community-acquired pneumonia in the emergency department. Curr Infect Dis Rep: 2014; 16 12 451
114. Kolditz M., Ewig S., Höffken G. Management-based risk prediction in community-acquired pneumonia by scores and biomarkers. Eur Respir J: 2013; 41 4 974 984
115. Mandell L. A., Wunderink R. G., Anzueto A., et al. Infectious Diseases Society of America; American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis: 2007; 44 02 S27 S72
116. Mello C. F., Negra M. D. Impact of macrolide therapy on mortality of HIV-infected patients with community-acquired pneumonia in a tertiary teaching hospital. Braz J Infect Dis: 2011; 15 3 262 267
117. Baddour L. M., Yu V. L., Klugman K. P., et al. International Pneumococcal Study Group. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med: 2004; 170 4 440 444
118. Curran A., Falcó V., Crespo M., et al. Bacterial pneumonia in HIV-infected patients: use of the pneumonia severity index and impact of current management on incidence, aetiology and outcome. HIV Med: 2008; 9 8 609 615
119. Cordero E., Pachón J., Rivero A., et al. Community-acquired bacterial pneumonia in human immunodeficiency virus-infected patients: validation of severity criteria. The Grupo Andaluz para el Estudio de las Enfermedades Infecciosas. Am J Respir Crit Care Med: 2000; 162 6 2063 2068
120. Chew K. W., Yen I. H., Li J. Z., Winston L. G. Predictors of pneumonia severity in HIV-infected adults admitted to an urban public hospital. AIDS Patient Care STDS: 2011; 25 5 273 277
121. Barakat L. A., Juthani-Mehta M., Allore H., et al. Comparing clinical outcomes in HIV-infected and uninfected older men hospitalized with community-acquired pneumonia. HIV Med: 2015; 16 7 421 430
122. Yone E. W., Balkissou A. D., Kengne A. P., Kuaban C. Influence of HIV infection on the clinical presentation and outcome of adults with acute community-acquired pneumonia in Yaounde, Cameroon: a retrospective hospital-based study. BMC Pulm Med: 2012; 12 46
123. Christensen D., Feldman C., Rossi P., et al. Community-Acquired Pneumonia Organization Investigators. HIV infection does not influence clinical outcomes in hospitalized patients with bacterial community-acquired pneumonia: results from the CAPO international cohort study. Clin Infect Dis: 2005; 41 4 554 556
124. Malinis M., Myers J., Bordon J., et al. Clinical outcomes of HIV-infected patients hospitalized with bacterial community-acquired pneumonia. Int J Infect Dis: 2010; 14 1 e22 e27
125. Bordon J., Kapoor R., Martinez C., et al. CD4+ cell counts and HIV-RNA levels do not predict outcomes of community-acquired pneumonia in hospitalized HIV-infected patients. Int J Infect Dis: 2011; 15 12 e822 e827
126. Feldman C., Glatthaar M., Morar R., et al. Bacteremic pneumococcal pneumonia in HIV-seropositive and HIV-seronegative adults. Chest: 1999; 116 1 107 114
127. Morris A. M., Huang L., Bacchetti P., et al. The Pulmonary Complications of HIV Infection Study Group. Permanent declines in pulmonary function following pneumonia in human immunodeficiency virus-infected persons. Am J Respir Crit Care Med: 2000; 162 2, Pt 1 612 616
128. Osmond D. H., Chin D. P., Glassroth J., et al. Pulmonary Complications of HIV Study Group. Impact of bacterial pneumonia and Pneumocystis carinii pneumonia on human immunodeficiency virus disease progression. Clin Infect Dis: 1999; 29 3 536 543
129. Feldman C., Anderson R. Review: current and new generation pneumococcal vaccines. J Infect: 2014; 69 4 309 325
130. Musher D. M. Pneumococcal vaccination in adults. UpToDate; April 2015, Available at: www.uptodate.com
131. WHO. Pneumococcal polysaccharide vaccine. WHO position paper; March: 2008;, Available at: http://www.who.int/immunization/sage/1-PPV23-draft-March-3-clean.pdf
132. Leventer-Roberts M., Feldman B. S., Brufman I., Cohen-Stavi C. J., Hoshen M., Balicer R. D. Effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive disease and hospital-treated pneumonia among people aged ≥65 years: a retrospective case-control study. Clin Infect Dis: 2015; 60 10 1472 1480
133. Russell K. L., Baker C. I., Hansen C., et al. Lack of effectiveness of the 23-valent polysaccharide pneumococcal vaccine in reducing all-cause pneumonias among healthy young military recruits: a randomized, double-blind, placebo-controlled trial. Vaccine: 2015; 33 9 1182 1187
134. Peñaranda M., Falco V., Payeras A., et al. Effectiveness of polysaccharide pneumococcal vaccine in HIV-infected patients: a case-control study. Clin Infect Dis: 2007; 45 7 e82 e87
135. Rodriguez-Barradas M. C., Goulet J., Brown S., et al. Impact of pneumococcal vaccination on the incidence of pneumonia by HIV infection status among patients enrolled in the Veterans Aging Cohort 5-Site Study. Clin Infect Dis: 2008; 46 7 1093 1100
136. Imaz A., Falcó V., Peñaranda M., et al. Impact of prior pneumococcal vaccination on clinical outcomes in HIV-infected adult patients hospitalized with invasive pneumococcal disease. HIV Med: 2009; 10 6 356 363
137. French N., Nakiyingi J., Carpenter L. M., et al. 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. Lancet: 2000; 355 9221 2106 2111
138. Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR Morb Mortal Wkly Rep: 2010; 59 34 1102 1106
139. Centers for Disease Control and Prevention (CDC) Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep: 2012; 61 40 816 819
140. Moore M. R., Link-Gelles R., Schaffner W., et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis: 2015; 15 3 301 309
141. Lepoutre A., Varon E., Georges S., et al. Microbiologists of Epibac; ORP Networks. Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001-2012. Vaccine: 2015; 33 2 359 366
142. Waight P. A., Andrews N. J., Ladhani S. N., Sheppard C. L., Slack M. P., Miller E. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. Lancet Infect Dis: 2015; 15 5 535 543
143. Chacon-Cruz E., Rivas-Landeros R. M., Volker-Soberanes M. L. Early trends in invasive pneumococcal disease in children following the introduction of 13-valent pneumococcal conjugate vaccine: results from eight years of active surveillance in a Mexican hospital. Ther Adv Vaccines: 2014; 2 6 155 158
144. Bonten M. J., Huijts S. M., Bolkenbaas M., et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med: 2015; 372 12 1114 1125
145. Tomczyk S., Bennett N. M., Stoecker C., et al. Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep: 2014; 63 37 822 825
146. Klugman K. P., Madhi S. A., Huebner R. E., Kohberger R., Mbelle N., Pierce N.; Vaccine Trialists Group. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med: 2003; 349 14 1341 1348
147. French N., Gordon S. B., Mwalukomo T., et al. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med: 2010; 362 9 812 822
148. Chan C. Y., Molrine D. C., George S., et al. Pneumococcal conjugate vaccine primes for antibody responses to polysaccharide pneumococcal vaccine after treatment of Hodgkin's disease. J Infect Dis: 1996; 173 1 256 258
149. Lesprit P., Pédrono G., Molina J. M., et al. ANRS 114-Pneumovac Study Group. Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults. AIDS: 2007; 21 18 2425 2434
150. Kumar D., Chen M. H., Wong G., et al. A randomized, double-blind, placebo-controlled trial to evaluate the prime-boost strategy for pneumococcal vaccination in adult liver transplant recipients. Clin Infect Dis: 2008; 47 7 885 892
151. Miernyk K. M., Butler J. C., Bulkow L. R., et al. Immunogenicity and reactogenicity of pneumococcal polysaccharide and conjugate vaccines in Alaska native adults 55-70 years of age. Clin Infect Dis: 2009; 49 2 241 248
152. Jackson L. A., Gurtman A., van Cleeff M., et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults. Vaccine: 2013; 31 35 3577 3584
153. Jackson L. A., Gurtman A., van Cleeff M., et al. Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older. Vaccine: 2013; 31 35 3594 3602
154. Greenberg R. N., Gurtman A., Frenck R. W., et al. Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults 60-64 years of age. Vaccine: 2014; 32 20 2364 2374
155. Iyer A. S., Leggat D. J., Ohtola J. A., et al. Response to pneumococcal polysaccharide vaccination in HIV-positive individuals on long term highly active antiretroviral therapy. J AIDS Clin Res: 2015; 6 2 421
156. Hibberd P. L. Immunizations in HIV-infected patients. UpToDate; May 2015; Available at: www.uptodate.com
157. Leggat D. J., Iyer A. S., Ohtola J. A., et al. Response to pneumococcal polysaccharide vaccination in newly diagnosed HIV-positive individuals. J AIDS Clin Res: 2015; 6 2 419
158. Rodriguez-Barradas M. C., Serpa J. A., Munjal I., et al. Quantitative and qualitative antibody responses to immunization with the pneumococcal polysaccharide vaccine in HIV-infected patients after initiation of antiretroviral treatment: results from a randomized clinical trial. J Infect Dis: 2015; 211 11 1703 1711
159. Engsig F. N., Zangerle R., Katsarou O., et al. Antiretroviral Therapy Cohort Collaboration (ART-CC) and the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord. Long-term mortality in HIV-positive individuals virally suppressed for >3 years with incomplete CD4 recovery. Clin Infect Dis: 2014; 58 9 1312 1321
160. Zoufaly A., Cozzi-Lepri A., Reekie J., et al. EuroSIDA in EuroCoord. Immuno-virological discordance and the risk of non-AIDS and AIDS events in a large observational cohort of HIV-patients in Europe. PLoS ONE: 2014; 9 1 e87160
161. Braitstein P., Brinkhof M. W., Dabis F., et al. Antiretroviral Therapy in Lower Income Countries (ART-LINC) Collaboration; ART Cohort Collaboration (ART-CC) groups. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet: 2006; 367 9513 817 824
162. Keiser O., Orrell C., Egger M., et al. Swiss HIV Cohort Study (SHCS) and the International Epidemiologic Databases to Evaluate AIDS in Southern Africa (IeDEA-SA). Public-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland compared. PLoS Med: 2008; 5 7 e148
163. Kantso B., Green N., Goldblatt D., Benfield T. Antibody response is more likely to pneumococcal proteins than to polysaccharide after HIV-associated invasive pneumococcal disease. J Infect Dis: 2015; 212 7 1093 1099
164. Mdodo R., Frazier E. L., Dube S. R., et al. Cigarette smoking prevalence among adults with HIV compared with the general population in the United States. Ann Intern Med: 2015; 162 5 335 344
165. McCullers J. A. Insights into the interaction between influenza virus and pneumococcus. Clin Microbiol Rev: 2006; 19 3 571 582
166. Remschmidt C., Wichmann O., Harder T. Influenza vaccination in HIV-infected individuals: systematic review and assessment of quality of evidence related to vaccine efficacy, effectiveness and safety. Vaccine: 2014; 32 43 5585 5592
167. Cohen C., Moyes J., Tempia S., et al. Mortality amongst patients with influenza-associated severe acute respiratory illness, South Africa, 2009-2013. PLoS ONE: 2015; 10 3 e0118884